Nasdaq GlobeNewswire

BELGRAVIA CAPITAL INTERNATIONAL receives cash payment, appoints renowned Dermatologist as special advisor to ICP Organics, and provides updates on additional blockchain developments

Del

TORONTO, Jan. 10, 2018 (GLOBE NEWSWIRE) -- BELGRAVIA CAPITAL INTERNATIONAL INC. (CSE:BLGV) (OTCQB:BLGVF) ("Belgravia Capital", "Belgravia", or the "Company") is pleased to announced that the second cash payment of USD $1.4 million, due from Cartesian Capital Group controlled Intercontinental Potash Corp. (USA) has been received.  The Canadian equivalent amount received is $1.74 million. Current working capital, prior to the completion of the current financing, announced on January 3, 2018, is CAD $5.1 million.

The Company is pleased to announce that Dr. Sam Hanna, a recognized Canadian dermatologist has been appointed as Special Advisor to Belgravia's wholly owned subsidiary, ICP Organics Corp. ("ICP Organics").  As announced on March 28, 2017, ICP Organics will focus on increasing the health impact and effects for consumers of medicinal cannabis in its various formats. Dr. Hanna, is a practicing dermatologist.  Cannabidiol ("CBD") is a cannabinoid found throughout the seeds, stalk and flowers of cannabis plants including hemp. Hemp and hemp derived CBD products are among the fastest growing segments in the cannabis industry. According to a report by market intelligence firm Hemp Business Journal the CBD market may grow to $2.1 billion by 2020.  According to a published study in the Journal of Clinical Investigation, published September 2014, there is sufficient scientific data to strongly encourage future study in clinical trials to determine whether either systemic or topical application of CBD and/or appropriate modulation of the related signalling pathways deserves full clinical exploration as a potent novel class of anti-acne agents. According to the Journal of the American Academy of Dermatology, as published in an article July 2017, Cannabinoids may have anti-inflammatory properties useful for the treatment of both allergic contact dermatitis and atopic dermatitis. 

Mr. Mehdi Azodi, the President and Chief Executive Officer of Belgravia stated: "We are very pleased to have Dr. Hanna join the advisory panel of ICP Organics, as we seek to expand our horizons in the legal medicinal cannabis business. In addition, we are continuing to develop the specifications for our blockchain concepts with respect to distributed databases as a service to retail consumers, and as a value-added technology for the medical cannabis industry. In addition to the developments, previously announced, we are investigating an additional blockchain concept, which may have the potential to provide a dramatic and significantly disruptive solution for certain aspects of customer generation and retention for licensed producers, and other distributors of legal cannabis products, around the world."

Mr. Azodi continued: "As previously announced the company has investments of approximately $675,000 in a developing portfolio of strategic research and development investments in companies which will provide value-added services to Belgravia in terms of profitable ideas and relationships in the legal medicinal cannabis industry and the blockchain sector.  Based on current working capital, and the shortly anticipated closing of the current financing, we expect to expand this strategic investment portfolio.  This will include taking an active role in the management of the operations of these investee companies in certain cases."

About Belgravia Capital
Belgravia Capital International is focused on the provision of clearly value-added services to the international legal Cannabis industry.  This includes the production of specialized organic fertilizers for Cannabis Sativa plants, and the organization and development of blockchain technology software for seed-to-sale tracking and quality attestation of intermediate and consumer products. The wholly owned subsidiary of Belgravia, ICP Organics, is a research and development company incorporating agronomic and health perspectives in the Cannabis space. Belgravia is also developing a royalty-streaming subsidiary.

Belgravia Capital intends to establish joint research and development partnerships with Licensed Producers operating under ACMPR regulations in Canada and in other jurisdictions where medicinal cannabis is fully legal. Belgravia Capital may invest in various private and public companies in diversified sectors on an opportunistic basis. For more information, please visit www.belgraviacapital.ca.

Forward-Looking Statements 
Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements include statements that use forward-looking terminology such as "may", "will", "expect", "anticipate", "believe", "continue", "potential" or the negative thereof or other variations thereof or comparable terminology. Such forward-looking statements include, without limitation, statements regarding planned investment activities & related returns, trends in the markets for fertilizers and medicinal or recreational use of cannabis, the timing or assurance of the legalization of recreational cannabis, the timing for completion of research and development activities, the potential value of royalties from water and other resources, and other statements that are not historical facts. These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond the control of the Company, including, but not limited to, changes in market trends, the completion, results and timing of research undertaken by the Company, risks associated with resource assets, the impact of general economic conditions, commodity prices, industry conditions, dependence upon regulatory, environmental, and governmental approvals, the uncertainty of obtaining additional financing, and risks associated with cannabis use for medicinal or recreational purposes. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements.

For More Information, Please Contact:
Mehdi Azodi, President & CEO
Belgravia Capital 
(416) 779-3268 
mazodi@blgv.ca 




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Belgravia Capital International via Globenewswire

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

Inspiration Updates Proposed Acquisition of Compassion Cannabis24.4.2018 17:00Pressemelding

TORONTO, April 24, 2018 (GLOBE NEWSWIRE) -- Inspiration Mining Corporation (CSE:ISM) (the "Corporation") is pleased to announce that its ongoing negotiations with Compassion Cannabis Corp ("Compassion") and the related due diligence is going very well and ahead of the targeted date. The Corporation has commenced discussions pertaining to the terms and conditions of a proposed share exchange agreement and the resulting structure of the Corporation's board of directors. Compassion is a private Ontario company which has expertise to forward various facets of the explosive new market of the marijuana industry, including but not limited to the "Vape" market and dispensary centers for the industry. The Corporation believes that this is an extremely lucrative space with tremendous demand in the medical cannabis industry. The cannabis market is growing exponentially every day with new and exciting innovations in the industry. Compassion has narrowed down its possible research and development l

Barings Supports Liberty Hall on Refinancing of AIM Aerospace24.4.2018 16:00Pressemelding

CHARLOTTE, N.C., April 24, 2018 (GLOBE NEWSWIRE) -- Barings, one of the world's leading financial services firms, announced today that it served as the sole agent and lead arranger on first lien senior credit facilities to support Liberty Hall Capital Partners' refinancing of the existing debt of its portfolio company, AIM Aerospace. AIM Aerospace, based in Renton, Washington, is a leading designer and producer of advanced composite structures, systems, engine components and thermoplastic technology for the global aerospace industry. The company supplies thermoset and thermoplastic composite solutions to Tier 1 aero-structure and aero-equipment suppliers and to aircraft original equipment manufacturers (OEMs). "Liberty Hall appreciates the partner-like approach that Barings brought to support our investment in AIM Aerospace," said Rowan Taylor, Liberty Hall's founding Partner. "Barings' creativity in structuring, ability to move quickly and speak for the entire facility helped expedite

Appian Announces Strategic Technology Alliance with Genesys24.4.2018 15:04Pressemelding

Companies align development, marketing, and sales to deliver intelligent case management for contact center excellence RESTON, Va., April 24, 2018 (GLOBE NEWSWIRE) -- Appian (NASDAQ:APPN) today announced a strategic technology alliance with Genesys®, the global leader in omnichannel customer experience and contact center solutions. The partnership will benefit organizations seeking next-generation customer engagement solutions that integrate the case management, intelligent automation, and low-code application development capabilities of Appian with the Genesys Customer Experience Platform. "Over the last several years, Serco has used Appian technology, alongside Genesys, to deliver contact solutions to its Federal customers, having processed tens of millions of cases across thousands of contact center agents through our systems. We are excited to hear about the tighter technology partnership between Appian and Genesys as it opens up the possibility to deliver more efficient solutions

Appian and KPMG Apply Artificial Intelligence to Create Business Value24.4.2018 15:03Pressemelding

Appian's low-code development platform operationalizes KPMG machine learning experience RESTON, Va., April 24, 2018 (GLOBE NEWSWIRE) -- Appian (NASDAQ:APPN) and KPMG LLP today announce an expansion of their strategic alliance. Together, the companies are focused on making it easier to realize the business value of artificial intelligence (AI) by combining the KPMG Ignite portfolio of AI services with the speed, features, and intelligent automation (IA) capabilities of Appian's low-code platform. KPMG and Appian will expand their relationship around AI-related applications, and Appian's platform will be leveraged by KPMG Lighthouse, a Center of Excellence for Data & Analytics, to demonstrate application and operational delivery of innovative AI services. AI technology holds immense promise for smarter decisions, faster action, and smoother business operations in scenarios ranging from frontline customer service to back-office risk management and regulatory compliance. Real-world deploym

Appian Announces the Intelligent Contact Center Platform24.4.2018 15:02Pressemelding

Makes it easier than ever to build unique and powerful contact center solutions by uniting low-code development with powerful AI, RPA, and Case Management RESTON, Va., April 24, 2018 (GLOBE NEWSWIRE) -- Appian (NASDAQ:APPN) today announced a new product for rapidly building unique contact center solutions that deliver unrivaled customer experiences. Appian Intelligent Contact Center Platform® is a new cloud platform tailored to the unique needs of contact center teams. The new platform inherits all of the core attributes of the Appian platform for building omni-channel customer engagement, case management, and intelligent automation solutions in a low-code development environment. In addition, Appian Intelligent Contact Center Platform provides native and integrated artificial intelligence (AI) capabilities and a host of strategic technology partnerships specific to the needs of the contact center. "We deliver and run contact center solutions for many of the largest financial services

Appian Announces Latest Version of the Appian Platform24.4.2018 15:01Pressemelding

RESTON, Va., April 24, 2018 (GLOBE NEWSWIRE) -- Today at the Appian World 2018 global user conference, Appian (NASDAQ:APPN) unveiled the latest version of Appian, the Digital Transformation Platform®. The new release makes it easier than ever to rapidly build powerful software applications. Enhancements to the platform help drive intelligent automation across the organization, optimize the designer and user experience across channels, and bolster performance and administration of Appian's platform-as-a-service (PaaS) cloud architecture. In addition to being in the core Appian platform, these enhancements are also available in the new Appian Intelligent Contact Center Platform®, announced today. "We deployed nine key risk mitigating applications on Appian in just 18 months," said Denise Knabjian, First Vice President of Process Innovation at OCC, the world's largest equity derivatives clearing house. "Appian is key to the flexible yet secure IT infrastructure we require given our design

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom